Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Comparison of costimulatory domains in combined GD2 chimeric antigen receptor T cell therapy and oncolytic vaccine therapy for neuroblastoma
EF 2018-19
Résumé
Neuroblastoma is a childhood cancer with a poor prognosis in advanced or relapsed disease. Chimeric antigen receptor (CAR) T cells is a promising new treatment for neuroblastoma. In this treatment, immune cells called T cells are engineered to selectively recognize and kill cancer cells. In the case of neuroblastoma, these CAR T cells recognize a molecule on the surface of the tumour cell called GD2. One important component of the CAR T cell is the costimulatory domain, which consists of either the molecule CD28, 41BB, or both in combination. It has been found that 41BB leads to a longer duration of CAR T cells in the body (persistence), which is associated with a better outcome for the patient. However, CD28 leads to improved killing initially. The combination of CD28 and 41BB appears to lead to enhanced function of the CAR T cell.
Initial studies of CAR T cells in solid tumors have encountered some challenges, including insufficient numbers of T cells and poor trafficking of the CAR T cells to the tumor. Our laboratory is interested in using viruses that specifically target tumor cells (oncolytic viruses) to overcome these challenges. We have found that by delivering the oncolytic virus after transfer of CAR T cells, the CAR T cell product is expanded, known as a viral boost. What remains unknown is which costimulatory domain leads to persistence and better function of the CAR T cell product after viral boost.
I propose to study GD2-CAR T cells with different costimulatory domains (CD28, 41BB or combined CD28/41BB). I hypothesize that 41BB will lead to improved persistence and function of the CAR T cell against GD2-expressing tumour cells.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406365
Name
Finkbeiner Melanie
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Comparison of costimulatory domains in combined GD2 chimeric antigen receptor T cell therapy and oncolytic vaccine therapy for neuroblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Car T Cell Therapy; Immunotherapy; Neuroblastoma; Oncolytic Viruses; Pediatric Cancer
Abstract
Neuroblastoma is a childhood cancer with a poor prognosis in advanced or relapsed disease. Chimeric antigen receptor (CAR) T cells is a promising new treatment for neuroblastoma. In this treatment, immune cells called T cells are engineered to selectively recognize and kill cancer cells. In the case of neuroblastoma, these CAR T cells recognize a molecule on the surface of the tumour cell called GD2. One important component of the CAR T cell is the costimulatory domain, which consists of either the molecule CD28, 41BB, or both in combination. It has been found that 41BB leads to a longer duration of CAR T cells in the body (persistence), which is associated with a better outcome for the patient. However, CD28 leads to improved killing initially. The combination of CD28 and 41BB appears to lead to enhanced function of the CAR T cell.
Initial studies of CAR T cells in solid tumors have encountered some challenges, including insufficient numbers of T cells and poor trafficking of the CAR T cells to the tumor. Our laboratory is interested in using viruses that specifically target tumor cells (oncolytic viruses) to overcome these challenges. We have found that by delivering the oncolytic virus after transfer of CAR T cells, the CAR T cell product is expanded, known as a viral boost. What remains unknown is which costimulatory domain leads to persistence and better function of the CAR T cell product after viral boost.
I propose to study GD2-CAR T cells with different costimulatory domains (CD28, 41BB or combined CD28/41BB). I hypothesize that 41BB will lead to improved persistence and function of the CAR T cell against GD2-expressing tumour cells.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Finkbeiner, Melanie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~